• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[Efficacy and safety of venetoclax and azacitidine in the treatment of refractory and relapsed acute myeloid leukemia].

作者信息

Zong L H, Wu X X, Zhang J, Li M Y, Song B Q, Kong J Y, Kong X, Hu X H, Bao X B, Qiu H Y, Wu D P

机构信息

The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, Suzhou 215006.

出版信息

Zhonghua Xue Ye Xue Za Zhi. 2021 Oct 14;42(10):861-864. doi: 10.3760/cma.j.issn.0253-2727.2021.10.012.

DOI:10.3760/cma.j.issn.0253-2727.2021.10.012
PMID:34788928
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8607025/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/914b/8607025/c54d8351f091/cjh-42-10-861-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/914b/8607025/c54d8351f091/cjh-42-10-861-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/914b/8607025/c54d8351f091/cjh-42-10-861-g001.jpg

相似文献

1
[Efficacy and safety of venetoclax and azacitidine in the treatment of refractory and relapsed acute myeloid leukemia].维奈克拉与阿扎胞苷治疗难治性和复发性急性髓系白血病的疗效与安全性
Zhonghua Xue Ye Xue Za Zhi. 2021 Oct 14;42(10):861-864. doi: 10.3760/cma.j.issn.0253-2727.2021.10.012.
2
Venetoclax and azacytidine combination is an effective bridge to transplant strategy in relapsed/refractory acute myeloid leukemia patients.维奈克拉与阿扎胞苷联合用药是复发/难治性急性髓系白血病患者移植策略的有效过渡方案。
Ann Hematol. 2021 Apr;100(4):1111-1113. doi: 10.1007/s00277-020-04333-7. Epub 2020 Nov 11.
3
Clinical responses in pediatric patients with relapsed/refractory leukemia treated with azacitidine and venetoclax.接受阿扎胞苷和维奈克拉治疗的复发/难治性白血病儿科患者的临床反应
Haematologica. 2023 Nov 1;108(11):3142-3147. doi: 10.3324/haematol.2022.282637.
4
[Venetoclax combined with azacitidine in the treatment of elderly patients with acute myeloid leukemia or myeloid sarcoma: Three cases reports and literature review].维奈托克联合阿扎胞苷治疗老年急性髓系白血病或髓系肉瘤：三例报告及文献综述
Zhonghua Xue Ye Xue Za Zhi. 2020 Aug 14;41(8):694-696. doi: 10.3760/cma.j.issn.0253-2727.2020.08.016.
5
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.在未经治疗的老年急性髓系白血病患者中，venetoclax 联合地西他滨或阿扎胞苷的安全性和初步疗效：一项非随机、开放标签、1b 期研究。
Lancet Oncol. 2018 Feb;19(2):216-228. doi: 10.1016/S1470-2045(18)30010-X. Epub 2018 Jan 12.
6
Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A.VIALE-A研究中接受维奈克拉和阿扎胞苷治疗的急性髓系白血病患者缓解后血细胞减少的管理
Am J Hematol. 2022 Nov;97(11):E416-E419. doi: 10.1002/ajh.26692. Epub 2022 Sep 16.
7
Efficacy and predictive factors of venetoclax combined with azacitidine as salvage therapy in advanced acute myeloid leukemia patients: A multicenter retrospective study.维奈托克联合阿扎胞苷作为晚期急性髓系白血病患者挽救治疗的疗效及预测因素：一项多中心回顾性研究
Leuk Res. 2020 Apr;91:106317. doi: 10.1016/j.leukres.2020.106317. Epub 2020 Feb 14.
8
Ex vivo drug sensitivity profiling-guided treatment of a relapsed pediatric mixed-phenotype acute leukemia with venetoclax and azacitidine.体外药敏分析指导下使用维奈克拉和阿扎胞苷治疗复发性儿童混合表型急性白血病
Pediatr Blood Cancer. 2022 Oct;69(10):e29678. doi: 10.1002/pbc.29678. Epub 2022 Mar 30.
9
Venetoclax plus azacitidine and LDAC induced high response rates in acute myeloid leukaemia in routine clinical practice.在常规临床实践中，维奈克拉联合阿扎胞苷及低剂量阿糖胞苷在急性髓系白血病中诱导出了高缓解率。
Br J Haematol. 2023 Jun;201(5):995-999. doi: 10.1111/bjh.18788. Epub 2023 Mar 31.
10
[Durable molecular remission in a patient with relapsed NPM1/IDH1 mutant acute myeloid leukemia treated with venetoclax combined with azacitidine: a case report].[维奈克拉联合阿扎胞苷治疗复发的NPM1/IDH1突变型急性髓系白血病患者实现持久分子缓解：一例报告]
Zhonghua Xue Ye Xue Za Zhi. 2022 Feb 14;43(2):166. doi: 10.3760/cma.j.issn.0253-2727.2022.02.017.

引用本文的文献

1
Efficacy and safety of venetoclax and azacitidine for acute myeloid leukemia in China: a real-world single-center study.维奈克拉与阿扎胞苷在中国治疗急性髓系白血病的疗效及安全性：一项真实世界单中心研究
BMC Cancer. 2025 Jun 3;25(1):990. doi: 10.1186/s12885-025-14167-z.

本文引用的文献

1
The efficacy and adverse events of venetoclax in combination with hypomethylating agents treatment for patients with acute myeloid leukemia and myelodysplastic syndrome: a systematic review and meta-analysis.venetoclax 联合低甲基化药物治疗急性髓系白血病和骨髓增生异常综合征患者的疗效和不良事件：系统评价和荟萃分析。
Hematology. 2020 Dec;25(1):414-423. doi: 10.1080/16078454.2020.1843752.
2
Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia.对患者样本进行综合分析，确定 venetoclax 疗效的生物标志物和急性髓系白血病的联合治疗策略。
Nat Cancer. 2020 Aug;1(8):826-839. doi: 10.1038/s43018-020-0103-x. Epub 2020 Aug 18.
3
Venetoclax and hypomethylating agents in FLT3-mutated acute myeloid leukemia.
维奈托克与去甲基化药物治疗FLT3突变的急性髓系白血病
Am J Hematol. 2020 Oct;95(10):1193-1199. doi: 10.1002/ajh.25929. Epub 2020 Jul 28.
4
Efficacy and predictive factors of venetoclax combined with azacitidine as salvage therapy in advanced acute myeloid leukemia patients: A multicenter retrospective study.维奈托克联合阿扎胞苷作为晚期急性髓系白血病患者挽救治疗的疗效及预测因素：一项多中心回顾性研究
Leuk Res. 2020 Apr;91:106317. doi: 10.1016/j.leukres.2020.106317. Epub 2020 Feb 14.
5
5-Azacitidine Induces NOXA to Prime AML Cells for Venetoclax-Mediated Apoptosis.5-氮杂胞苷诱导 NOXA 使 AML 细胞对 Venetoclax 介导的凋亡敏感。
Clin Cancer Res. 2020 Jul 1;26(13):3371-3383. doi: 10.1158/1078-0432.CCR-19-1900. Epub 2020 Feb 13.
6
Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.白血病遗传学与复发/难治性急性髓系白血病对维奈托克和去甲基化药物反应的关联
Am J Hematol. 2019 Oct;94(10):E253-E255. doi: 10.1002/ajh.25567. Epub 2019 Jul 10.
7
Venetoclax-based therapies for acute myeloid leukemia.基于 Venetoclax 的急性髓系白血病疗法。
Best Pract Res Clin Haematol. 2019 Jun;32(2):145-153. doi: 10.1016/j.beha.2019.05.008. Epub 2019 May 24.
8
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.维奈托克联合地西他滨或阿扎胞苷治疗初治老年急性髓系白血病患者。
Blood. 2019 Jan 3;133(1):7-17. doi: 10.1182/blood-2018-08-868752. Epub 2018 Oct 25.
9
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.在未经治疗的老年急性髓系白血病患者中，venetoclax 联合地西他滨或阿扎胞苷的安全性和初步疗效：一项非随机、开放标签、1b 期研究。
Lancet Oncol. 2018 Feb;19(2):216-228. doi: 10.1016/S1470-2045(18)30010-X. Epub 2018 Jan 12.
10
Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Venetoclax 联合治疗复发/难治性急性髓系白血病及相关髓系恶性肿瘤的临床经验。
Am J Hematol. 2018 Mar;93(3):401-407. doi: 10.1002/ajh.25000. Epub 2017 Dec 23.